FDA Paves Way for Generic Heparin After Safety Review
August 26, 2025
August 26, 2025
WASHINGTON, Aug. 26 (TNSFR) -- The U.S. Department of Health and Human Services Food and Drug Administration has given the go-ahead for generic versions of four heparin sodium injectable products.
FDA's decision follows a review that determined the original products, previously withdrawn from the market, were not removed for reasons related to their safety or effectiveness. This determination is a critical step that allows other companies to submit abbreviated drug applications . . .
FDA's decision follows a review that determined the original products, previously withdrawn from the market, were not removed for reasons related to their safety or effectiveness. This determination is a critical step that allows other companies to submit abbreviated drug applications . . .